Compare Travere Therapeutics Inc. Common Stock (TVTX) vs VICI Properties Inc (VICI) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

VICI Properties trades at $22.91, down 0.52% on the day, with a bearish technical signal despite strong fundamentals including a 67.5% net income margin and 9.84% ROE. The stock shows mixed earnings performance with one beat and two misses in recent quarters, while analyst consensus remains strongly bullish with a $28.90 price target representing 26% upside. Recent corporate actions include a $0.46 dividend payment scheduled for October 2026.

The investment case balances attractive valuation metrics (P/E of 8.88, P/B of 0.86) against technical weakness and tenant concentration risks. While cash flow generation remains robust with $2.51B from operations in 2025, investors face headwinds from rising interest rates and potential tenant stress. The 75% buy rating from analysts suggests significant upside potential if execution remains strong.